Literature DB >> 12107109

Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.

Tsuyoshi Watanabe1, Masatoshi Ichihara, Mizuo Hashimoto, Keiko Shimono, Yoshie Shimoyama, Tetsuro Nagasaka, Yoshiki Murakumo, Hideki Murakami, Hideshi Sugiura, Hisashi Iwata, Naoki Ishiguro, Masahide Takahashi.   

Abstract

Germ-line point mutations of the RET gene are responsible for multiple endocrine neoplasia (MEN) type 2A and 2B that develop medullary thyroid carcinoma and pheochromocytoma. We performed a differential display analysis of gene expression using NIH 3T3 cells expressing the RET-MEN2A or RET-MEN2B mutant proteins. As a consequence, we identified 10 genes induced by both mutant proteins and eight genes repressed by them. The inducible genes include cyclin D1, cathepsins B and L, and cofilin genes that are known to be involved in cell growth, tumor progression, and invasion. In contrast, the repressed genes include type I collagen, lysyl oxidase, annexin I, and tissue inhibitor of matrix metalloproteinase 3 (TIMP3) genes that have been implicated in tumor suppression. In addition, six RET-MEN2A- and five RET-MEN2B-inducible genes were identified. Among 21 genes induced by RET-MEN2A and/or RET-MEN2B, six genes including cyclin D1, cathepsin B, cofilin, ring finger protein 11 (RNF11), integrin-alpha6, and stanniocalcin 1 (STC1) genes were also induced in TGW human neuroblastoma cells in response to glial cell line-derived neurotrophic factor stimulation. Because the STC1 gene was found to be highly induced by both RET-MEN2B and glial cell line-derived neurotrophic factor stimulation, and the expression of its product was detected in medullary thyroid carcinoma with the MEN2B mutation by immunohistochemistry, this may suggest a possible role for STC1 in the development of MEN 2B phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107109      PMCID: PMC1850689          DOI: 10.1016/S0002-9440(10)64176-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

Review 1.  Proteoglycans of the extracellular matrix and growth control.

Authors:  H Kresse; E Schönherr
Journal:  J Cell Physiol       Date:  2001-12       Impact factor: 6.384

2.  Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors.

Authors:  T Andreú; T Beckers; E Thoenes; P Hilgard; H von Melchner
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

3.  Evidence for stanniocalcin gene expression in mammalian bone.

Authors:  Y Yoshiko; A Son; S Maeda; A Igarashi; S Takano; J Hu; N Maeda
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

4.  cAMP signaling can antagonize potent glucocorticoid post-transcriptional inhibition of stanniocalcin gene expression.

Authors:  T C Groves; G F Wagner; G E DiMattia
Journal:  J Endocrinol       Date:  2001-12       Impact factor: 4.286

5.  Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.

Authors:  T Iwashita; M Kato; H Murakami; N Asai; Y Ishiguro; S Ito; Y Iwata; K Kawai; M Asai; K Kurokawa; H Kajita; M Takahashi
Journal:  Oncogene       Date:  1999-07-01       Impact factor: 9.867

6.  Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.

Authors:  H Murakami; T Iwashita; N Asai; Y Shimono; Y Iwata; K Kawai; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1999-08-19       Impact factor: 3.575

7.  High expression of stanniocalcin in differentiated brain neurons.

Authors:  K Z Zhang; J A Westberg; A Paetau; K von Boguslawsky; P Lindsberg; M Erlander; H Guo; J Su; H S Olsen; L C Andersson
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Studies on the regulation and characterization of plasma stanniocalcin in rainbow trout.

Authors:  G F Wagner; C Milliken; H G Friesen; D H Copp
Journal:  Mol Cell Endocrinol       Date:  1991-08       Impact factor: 4.102

9.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

10.  Essential role of alpha 6 integrins in cortical and retinal lamination.

Authors:  E Georges-Labouesse; M Mark; N Messaddeq; A Gansmüller
Journal:  Curr Biol       Date:  1998-08-27       Impact factor: 10.834

View more
  15 in total

Review 1.  Advances in understanding functional variations in the Hirschsprung disease spectrum (variant Hirschsprung disease).

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2016-12-17       Impact factor: 1.827

2.  Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.

Authors:  Thomas J Musholt; Julia Hanack; Christoph Brehm; Reinhard von Wasielewski; Petra B Musholt
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

Review 3.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

4.  Actin depolymerizing factors cofilin1 and destrin are required for ureteric bud branching morphogenesis.

Authors:  Satu Kuure; Cristina Cebrian; Quentin Machingo; Benson C Lu; Xuan Chi; Deborah Hyink; Vivette D'Agati; Christine Gurniak; Walter Witke; Frank Costantini
Journal:  PLoS Genet       Date:  2010-10-28       Impact factor: 5.917

5.  Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients.

Authors:  Haizhu Song; Biao Xu; Jun Yi
Journal:  J Exp Clin Cancer Res       Date:  2012-04-26

Review 6.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

7.  Ret-dependent and Ret-independent mechanisms of Gfl-induced sensitization.

Authors:  Brian S Schmutzler; Shannon Roy; Sherry K Pittman; Rena M Meadows; Cynthia M Hingtgen
Journal:  Mol Pain       Date:  2011-03-30       Impact factor: 3.395

8.  How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.

Authors:  Hugo Prazeres; Joana Torres; Fernando Rodrigues; Joana P Couto; João Vinagre; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Thyroid Res       Date:  2011-06-23

9.  Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis.

Authors:  Benson C Lu; Cristina Cebrian; Xuan Chi; Satu Kuure; Richard Kuo; Carlton M Bates; Silvia Arber; John Hassell; Lesley MacNeil; Masato Hoshi; Sanjay Jain; Naoya Asai; Masahide Takahashi; Kai M Schmidt-Ott; Jonathan Barasch; Vivette D'Agati; Frank Costantini
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

10.  Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells.

Authors:  Fengjie Guo; Yalin Li; Jiajia Wang; Yandong Li; Yuehui Li; Guancheng Li
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.